Caudwell Xtreme Everest
Caudwell Xtreme Everest (CXE) was the first flagship project of the Centre for Altitude Space 1,2 and Extreme Environment Medicine (CASE), 3 established at University College London in 2000. CASE has grown around the premise that valuable data of clinical relevance can be obtained by studying human physiology under conditions of dynamic stress resulting from exposure to extreme environments. 4 The Centre brings together individuals interested in the physiology and pathophysiology of a variety of extreme environments (altitude, space and aerospace, diving and hyperbaric, thermal stress), who teach and undertake research in these areas.
The implications and relevance of high altitude physiology and pathophysiology for intensive care medicine are discussed in detail elsewhere. 5 Supportive of the concept that there are parallels between these apparently distinct situations, is the observation that allelic variants of a ubiquitously expressed gene (angiotensin-converting enzyme) are associated with a beneficial phenotype in both critical illness and at high altitude. The ACE-I allele is associated with improved outcome in several critical illnesses where cellular hypoxia is present (Adult Respiratory Distress Syndrome, 6 childhood Meningococcal Septicaemia 7 ) and with improved performance at high altitude. 8 The idea of CXE grew over seven years from idle pub talk to an endeavour involving more than 60 investigators in Nepal during the spring of 2007. The main study was preceded by several years of sea-level validation and pilot work, and by two other Himalayan expeditions over 8,000 metres. These were essential to ensure that the investigators and equipment could function effectively at extreme altitude, and that the experiments were feasible. For the Everest study, separate teams were responsible for research organisation, logistics, trekker support and public relations. At the same time, a small number of climbing researchers, selected from the main investigator group, were ascending up to and beyond 8,000 metres. The climbers collected unique data at purpose-built laboratories in the Western Cwm (6,400 metres) (Figure 1 ) and on the South Col (7,950 metres) of Everest (Figure 2 ). The highest data were obtained at 8,400 metres, where arterial blood gases were drawn from four subjects during the descent from the summit.
Can altitude research benefit critically ill patients?

M Grocott
The Caudwell Xtreme Everest (CXE) expedition in the spring of 2007 was a large field-study investigating adaptive responses to hypoxia, and was supported by a grant from the Intensive Care Foundation. This article sets out to explain why the CXE team went to Everest, what they hope to learn, and discusses some of the key studies. 
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Whilst the measurements made high on the mountain may seem the most intriguing (Figure 3) , the greater scientific yield will derive from more than 200 healthy volunteers progressively exposed to hypobaric hypoxia whilst trekking to Everest Base Camp. Similarly, although much of the publicity has focused on the climbers and experiments at the most extreme altitudes, the study was more crucially dependent on the investigators working at lower altitudes and on three other groups of people: the commitment, both personal and financial, of the volunteers who consented to be studied along the route to Base Camp; the strength and companionship of the Sherpas who carried the scientific equipment high on the mountain; and the engagement and support of our sponsors, were all invaluable and critical to the success of CXE (see Acknowledgements).
An important element of the CXE study design was that all subjects followed an identical ascent profile and thus an identical pattern of hypoxic exposure. During the ascent, exercise capacity, exercise efficiency, tissue oxygenation (brain and muscle near-infra-red spectroscopy), spirometry and neurological function (pupillometry, neurocognitive test battery) were recorded in four laboratories set up by the expedition. Members of the investigational team who were also subjects had more invasive studies, including continuous cardiac output measurement, gastrointestinal tonometry and muscle biopsies. A small parallel study, the Smiths Medical Young Everest Study, followed nine children aged 6 years and older as they ascended to a more moderate altitude (<4,000 metres).
Two core hypotheses are central to the CXE study. First, that differences between individuals in their performance at altitude will be explained by relative variations in 'metabolic efficiency' (ratio of oxygen consumption and work rate) and/or microcirculatory function (neither sea-level performance [fitness], nor variation in physiological variables thought to be crucial to successful acclimatisation, currently explain dramatic inter-individual performance variations). Second, that interindividual variation in phenotypic adaptation is related to variation in the frequency of different alleles of polymorphic genes. The identification of specific alleles associated with specific beneficial or maladaptive phenotypes will assist in the elucidation of mechanisms. Our hope is that this genotypephenotype approach in healthy subjects exposed to the dynamic challenge of exercise in a hypoxic environment will identify physiological and biochemical mechanisms, as well as their genetic associations, which will be important in clarifying the adaptive processes that critically ill patients undergo in conditions where cellular hypoxia is present.
The role of the Intensive Care Foundation
The Intensive Care Foundation (ICF) 9 was established in June 2003 to fulfill the Intensive Care Society' s constitutional mandate to promote critical care research; it aims to facilitate and support critical care research by members of the Society. Early high-profile successes have included pilot-funding of the TracMan study, 10 which subsequently received core MRC support. The ICF have also supported a variety of other research projects, and CXE has been one of these beneficiaries. Following special application and peer review the ICF awarded CXE a grant of £50,000 over two years (2007) (2008) . The grant is specifically to support the studies investigating changes in 'metabolic efficiency' occurring at high altitude, recognising that this work has potential benefit for critically ill patients. 
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Metabolic efficiency
Confirmation of beneficial human adaptation at altitude by means of a relative improvement in metabolic efficiency would suggest the possibility that therapies might be developed to improve the efficiency of oxygen use in patients. Putative mechanisms include uncoupling proteins, substrate shifts and down-regulation of 'non-essential' cellular activity (all have been observed in animal studies). Similar mechanisms may also be important for beneficial adaptation in patients with multiple organ failure. 11 Breath-by-breath respiratory gas analysis (Cardiopulmonary Exercise Testing, CPX), using ramp and steady-state protocols, was used to calculate the relationship between oxygen consumption and external work and thereby explore relative individual variation in 'metabolic efficiency.' Similar methods are currently being used in several hospitals around the UK to evaluate risk in patients undergoing major surgery. Investigators and equipment from the CXE study are currently engaged in an NIHR-supported project to evaluate the effectiveness of this approach in a randomised controlled trial. 12 The detailed phenotype data obtained from a longitudinal study in a large population will be related back to subject' s genetic profiles in order to identify alleles associated with beneficial or maladaptive adaptation. In a subset of the investigators who were subjects, muscle biopsies were obtained before the expedition and at base camp. These tissue samples will allow us to explore the transcriptome and proteome, mapping transcription and expression patterns in key metabolic pathways, and may in turn lead to identification of novel candidates for the genetic analysis.
CXE encompassed 34 ethically-approved protocols including more than 40 separate experiments. The study involved more than 11 person-years of progressive hypoxic exposure in more than 220 subjects. The result is a vast store of unique information; data entry on the main study database was completed in December 2007; exercise test analysis should be completed by June 2008. The final dataset will include results from 2,000 exercise tests, 10,000 blood tests and more than 250,000 data points collected in daily diaries of simple physiological variables and symptom scores.
Conclusion
The strength of CXE is in the systematic tightly controlled characterisation of the hypoxic phenotypes in the large group of volunteer trekkers, and the integration of this with genetic data. Fascinating, although less systematic, are the 'edge of the envelope' measurements made high on Everest that will provide a unique snapshot of human physiology close to its limits. The opportunity to explore the clinical implications of these findings in translational studies is the new challenge.
